Results 181 to 190 of about 210,652 (235)

Elexacaftor/Tezacaftor/Ivacaftor Population Pharmacokinetics in Pediatric Patients With Cystic Fibrosis. [PDF]

Clin Transl Sci
Truong NH, Benaboud S, Bouazza N, Barboura M, Bardin E, Miralles M, Lui G, Froelicher-Bournaud L, Rouillon S, Bihouee T, Bui S, Reix P, Dalphin ML, Laurans M, Languepin J, Corvol H, Troussier F, Weiss L, Cinthia R, Tatopoulos A, Deneuville E, Chiron R, Stremler N, Llerena C, Ramel S, Perisson C, Houdoin V, Mittaine M, Treluyer JM, Sermet-Gaudelus I, Foissac F, MODUL‐CF study group.   +31 more
europepmc   +1 more source

Survival of quick problem solver! [PDF]

Evol Med Public Health
Tez M.
europepmc   +1 more source

Impact of the expanded label for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del variant in the USA. [PDF]

Eur Respir J
Cromwell EA, Ostrenga JS, Sanders DB, Morgan W, Castellani C, Szczesniak R, Burgel PR.   +6 more
europepmc   +1 more source

Comparison of interrupted and continuous modulator therapy in cystic fibrosis: a real life experience in Turkey. [PDF]

Front Pediatr
Ergenekon AP, Selcuk M, Unal G, Gozen Bayramoğlu G, Altuntas C, Kose M, Basaran AE, Can Oksay S, Uytun S, Oktem S, Uyan ZS, Canitez Y, Demir E, Sen V, Karakulak V, Erdem Eralp E, Karadag B, Karakoc F, Pekcan S, Sismanlar Eyuboğlu T, Cakır E, Gokdemir Y.   +21 more
europepmc   +1 more source

Electrochromic, Capacitive, and Electrocatalytic Performance of TEMPO Anchored EDOT-SN(T)S-EDOT Electrode. [PDF]

ACS Omega
Nemutlu B, Eker EF, Önal AM, Cansu Ergun EG, Tanyeli C.   +4 more
europepmc   +1 more source

Building Lay Society Knowledge and Education for Health Technology Assessment and Policy Engagement: Case of CFTR Modulator Access in Brazil. [PDF]

Healthcare (Basel)
de Oliveira VSB, Amaral MB, Camargo M, Lopes-Pacheco M.   +3 more
europepmc   +1 more source

Bone Health in Young Individuals with Primary Ciliary Dyskinesia: Insights from a Comparison with Cystic Fibrosis and Healthy Controls.

Horm Res Paediatr
Gaupmann R, Schmidthaler K, Korajac A, Cobb K, Gruber S, Raimann A, Kent K, Burghardt AJ, Long J, Leonard M, Szépfalusi Z, Patsch JM, Dehlink E.   +12 more
europepmc   +1 more source

Effect of cystic fibrosis modulator therapies on serum levels of fat-soluble vitamins. [PDF]

JPGN Rep
Crehuá-Gaudiza E, Vicente Santamaría S, Álvarez Beltrán M, Martín Fernández C, Tutau Gómez C, Loverdos Eseverri I, García Romero R, Torcuato Rubio E, Del Brío Castillo R, Garriga García M, Gascón Galindo C, Gutiérrez Martínez JR, Castro Millán AM, Sierra San Nicolás S, Ortiz Pérez P, García Volpe C, Salcedo Lobato E, De La Mano Hernández A, Fernández González SM, Reyes Domínguez A, Peña-Quintana L, González Jiménez D, Cystic Fibrosis and Pancreas Working Group of the Spanish Gastroenterology, Hepatology and Nutrition Paediatric Society (SEGHNP).   +23 more
europepmc   +1 more source

A Novel LC-MS/MS Method for the Measurement of Elexacaftor, Tezacaftor and Ivacaftor in Plasma, Dried Plasma Spot (DPS) and Whole Blood in Volumetric Absorptive Microsampling (VAMS) Devices. [PDF]

Pharmaceutics
Pigliasco F, Cafaro A, Barco S, Cresta F, Casciaro R, Pedemonte N, Mattioli F, Castellani C, Cangemi G.   +8 more
europepmc   +1 more source

Pro-Opiomelanocortin and Melanocortin Receptor 3 and 4 Mutations in Genetic Obesity. [PDF]

Biomolecules
Yanik T, Durhan ST.
europepmc   +1 more source